CA 15.3 determination in patients with breast cancer: Clinical utility for the detection of distant metastases

Emilio Bombardieri, Maria Pizzichetta, Paolo Veronesi, Ettore Seregni, Anna Bogni, Lorenzo Maffioli, Gloria Saccani Jotti, Maria Antonietta Bassetto, Stefano Zurrida, Alberto Costa

Research output: Contribution to journalArticlepeer-review

Abstract

In 81 healthy women, 26 pregnant women, 25 patients with fibrocystic disease and 144 breast cancer patients, the overall diagnostic sensitivity and specificity of the CA 15.3 test was 27 and 97%, respectively. The positive and negative predictive values were 93 and 43%. In 150 node-negative patients taking part in a chemoprevention trial CA 15.3 was assayed at baseline and every 4 months for a median follow-up of 24 months (range 4-48). In these patients, 5 had local recurrences, 1 had a regional recurrence, 9 had distant metastases and 3 developed cancer in the contralateral breast. Among the patients with recurrences, those with distant metastases showed the highest ratio of CA 15.3 increase ( 8 9); in local and regional recurrences, this ratio was lower ( 2 6). The patients with contralateral breast cancer had no significant increase in CA 15.3. Patients in whom metastases were detected showed an increase in CA 15.3 4-48 months before clinical or instrumental detection of the metastases.

Original languageEnglish
Pages (from-to)144-146
Number of pages3
JournalEuropean Journal of Cancer
Volume29
Issue number1
DOIs
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'CA 15.3 determination in patients with breast cancer: Clinical utility for the detection of distant metastases'. Together they form a unique fingerprint.

Cite this